• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Young Pharmacists >Evaluation of Therapeutic Efficacy and Health Related Quality of Life of Anthracyclines Regimen and Taxanes with Anthracyclines Regimen in Node Positive Breast Cancer
【24h】

Evaluation of Therapeutic Efficacy and Health Related Quality of Life of Anthracyclines Regimen and Taxanes with Anthracyclines Regimen in Node Positive Breast Cancer

机译：蒽环类药物和紫杉类类药物与蒽环类药物治疗结节阳性乳腺癌的疗效和健康相关的生活质量评估

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Chemotherapy with anthracyclines/taxanes is considered as an effective treatment option for breast cancer. Adjuvant chemotherapeutic options with anthracyclines or taxanes have improved disease free survival and overall survival rates in early breast cancer. The study is aimed to compare the therapeutic efficacy of anthracyclines containing regimen and sequential administration of taxanes with anthracyclines regimen for NODE positive breast cancer patients and to assess the Health-Related Quality of Life (HRQOL) of treated patients. Methods: This prospective open label study involved 14 patients who were treated with 6 cycles of 5-Fluorouracil (500mg/msup2/sup), Doxorubicin (50mg/msup2/sup), Cyclophosphamide (500mg/msub2/sub) [FAC] and 10 patients with 6 cycles of FAC plus 4 cycles of Paclitaxel (225mg/msup2/sup) [PAC]. Paired sample T test was used to assess the disease-free survival and reoccurrence rate. Time to progression was assessed by Kaplan Meir analysis and independent sample T test was used for assessing all the HRQOL parameters. Results: The disease-free survival was evaluated between the baseline and after 2 months of the chemotherapy which showed significant difference ( p 0.05) in the patients treated with FAC regimen. Further, significant difference ( p 0.05) was also seen in the comparison of the first and end reports of chest x-ray during stage 3b. There was a significant improvement ( p 0.05) in the quality of life in the patients treated with FAC with adjuvant Paclitaxel during the 3rd cycle. Conclusion: The study outcomes recommend that sequential administration of Paclitaxel with FAC can give more treatment benefit in stage 3 breast cancer.
机译：背景：蒽环类/紫杉烷类化学疗法被认为是乳腺癌的有效治疗选择。蒽环类药物或紫杉烷类药物的辅助化疗方案可改善早期乳腺癌的无病生存期和总体生存率。这项研究旨在比较含蒽环类药物的方案和紫杉烷类药物的顺序给药与蒽环类方案对NODE阳性乳腺癌患者的疗效，并评估所治疗患者的健康相关生活质量（HRQOL）。方法：这项前瞻性开放标签研究涉及14例患者，这些患者接受6个周期的5-氟尿嘧啶（500mg / m 2 ），阿霉素（50mg / m 2 ），环磷酰胺治疗（500mg / m 2 ）[FAC]和10例患者采用6个周期的FAC加4个周期的紫杉醇（225mg / m 2 ）[PAC]。配对样本T检验用于评估无病生存率和复发率。通过Kaplan Meir分析评估进展时间，并使用独立样本T检验评估所有HRQOL参数。结果：评估了基线与化疗2个月后的无病生存期，显示接受FAC方案的患者有显着差异（p <0.05）。此外，在阶段3b期间的胸部X光检查的第一次和结束报告的比较中，也发现了显着差异（p <0.05）。在第3个周期中，接受FAC联合紫杉醇辅助治疗的患者的生活质量有显着改善（p <0.05）。结论：研究结果提示，紫杉醇与FAC的顺序给药可在3期乳腺癌中带来更多的治疗益处。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号